1. Yoshimura, Takuro, Miyoshi, Hiroaki, Shimono, Joji, Kohno, Kei, Ohshima, Koichi. 2022. CD37 expression in follicular lymphoma. In Annals of hematology, 101, 1067-1075. doi:10.1007/s00277-022-04785-z. https://pubmed.ncbi.nlm.nih.gov/35171311/
2. Caulier, Benjamin, Joaquina, Sandy, Gelebart, Pascal, Inderberg, Else Marit, Wälchli, Sébastien. 2024. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia. In Cell reports. Medicine, 5, 101572. doi:10.1016/j.xcrm.2024.101572. https://pubmed.ncbi.nlm.nih.gov/38754420/
3. Robak, Tadeusz, Robak, Pawel. 2014. Anti-CD37 antibodies for chronic lymphocytic leukemia. In Expert opinion on biological therapy, 14, 651-61. doi:10.1517/14712598.2014.890182. https://pubmed.ncbi.nlm.nih.gov/24555705/
4. Mougiakakos, Dimitrios. . Anti-CD37 CAR T cells: another arrow in the quiver. In Blood, 144, 1133-1134. doi:10.1182/blood.2024025361. https://pubmed.ncbi.nlm.nih.gov/39264608/
5. Bobrowicz, Malgorzata, Kusowska, Aleksandra, Krawczyk, Marta, Prochorec-Sobieszek, Monika, Winiarska, Magdalena. 2024. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies. In Oncoimmunology, 13, 2362454. doi:10.1080/2162402X.2024.2362454. https://pubmed.ncbi.nlm.nih.gov/38846084/
6. Elfrink, Suraya, Ter Beest, Martin, Janssen, Luuk, Scheijen, Blanca, van Spriel, Annemiek B. . IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. In Blood advances, 6, 2254-2266. doi:10.1182/bloodadvances.2021004366. https://pubmed.ncbi.nlm.nih.gov/35086136/
智鼠故事 
